Drug resistance among clinical isolates of frequently encountered bacterial species in Central Europe during 1975-1995

被引:41
作者
Kresken, M
Hafner, D
机构
[1] Rhone Poulenc Rorer Arzneimittel GmbH, D-50829 Cologne, Germany
[2] Univ Dusseldorf, Inst Pharmakol, D-40225 Dusseldorf, Germany
关键词
Gentamicin; Glycopeptide; Imipenem; Teicoplanin; Resistance Rate;
D O I
10.1007/BF02561661
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
A multicenter study for monitoring antimicrobial drug resistance in clinical isolates of the family Enterobacteriaceae, Pseudomonas aeruginosa, Staphylococcus and Enterococcus species in central Europa conducted by the Study Group Bacterial Resistance of the Paul-Ehrlich-Society for Chemotherapy has been ongoing since 1975, Between 1975 and 1995 susceptibility data on almost 60,000 bacteria, which were isolated and sampled under a common protocol by laboratories from Austria, Germany and Switzerland, were collected, These bacterial isolates were known by the respective investigators to have caused infections, From 1975 to the mid-80s none of the bacterial species examined showed an increase in resistance. The frequency of resistance in klebsiellae and Staphylococcus aureus to some antibiotics even declined. In 1990 and particularly in 1995, a clear increase in resistance for a number of antibiotic-organism pairs was observed. Resistance rates to fluoroquinolones increased in all species under investigation. In Escherichia coli the increase of resistance to ampicillin, co-trimoxazole and gentamicin was remarkable. Resistance to imipenem increased in P. aeruginosa. Resistance to cephalosporins, on the other hand, remained largely unchanged in gram-negative bacilli. Between 1990 and 1995, the prevalence of oxacillin resistance increased from 1.7 to 12.9% in S, aureus and from 15.8 to 55.8% in coagulase-negative staphylococci, whereas staphylococcal and enterococcal resistance to glycopeptides was still rare.
引用
收藏
页码:S2 / S8
页数:7
相关论文
共 9 条
  • [1] *DIN DTSCH I NORM, 1998, 58940 DIN 3
  • [2] *DIN DTSCH I NORM, 1998, 58940 DIN 4
  • [3] DUBOIS SK, 1995, J ANTIMICROB CHEMOTH, V35, P7
  • [4] Feinman SE, 1998, ASM NEWS, V64, P24
  • [5] Drug therapy - Antimicrobial-drug resistance
    Gold, HS
    Moellering, RC
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (19) : 1445 - 1453
  • [6] KRESKEN M, 1987, FORTSCHRITTE ANTIMIK, V6, P869
  • [7] Lederberg J, 1992, EMERGING INFECT MICR
  • [8] Monnet DL, 1998, INFECT CONT HOSP EP, V19, P388
  • [9] The challenges of emerging infectious diseases - Development and spread of multiply-resistant bacterial pathogens
    Tenover, FC
    Hughes, JM
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 275 (04): : 300 - 304